People from the pharmaceutical industry across the Straits call for strengthening cooperation in new drug research and development

The second cross strait biotechnology and new drug industry cooperation and exchange meeting was held in Beijing on March 21-22, with more than 20 major new drug enterprises from both sides participating in the exchange Participants appealed that at present, the process of cross-strait pharmaceutical cooperation is slow Next, we should strengthen legal convergence and establish cross-strait drug docking, mutual recognition and access platforms Lu Kongming, chairman of Zhongtian biotechnology group, the largest new drug development group in Taiwan, pointed out at the second cross strait biotechnology and new drug industry cooperation and exchange meeting that the document 44 issued by the mainland last year opened a new era of new drugs At present, we should seize the opportunity to strengthen cross-strait cooperation and promote the process of the mainland from generic drugs to new drugs On August 18, 2015, the State Council issued the opinions of the State Council on reforming the review and approval system for pharmaceutical and medical devices (GF (2015) No 44), which adjusted the definition of new drugs and generic drugs Adjust the new drug from "drugs not listed and sold in China" to "drugs not listed and sold in China and abroad" The generic drugs were changed from "imitating the drugs with national standards" to "imitating the drugs with the same treatment and effect as the original drugs" "After the promulgation of document 44, the mainland separated new drugs from generic drugs, in other words, opened a new era of new drugs." Lu said that the past environment and regulations in the mainland have led to the market dominated by generic drugs In the past, it was not easy for some mainland enterprises to cooperate with Taiwan because they did not see the value of new drugs "Now the No 44 document is all inclusive It must be innovative drugs from all over the world that are new drugs The new deal requires innovative drugs to be able to interface with and compete with the world So I think this is a good time for the mainland and Taiwan to strengthen cooperation again." After the issuance of No.44 document, new drug and clinical trial management policies have been issued in succession, including preferential policies for rapid review of special innovative R & D new drugs, encouragement of multi center clinical trials in many countries, improvement of review efficiency and transparency, etc., so as to substantially accelerate the layout of new drug research and development in mainland China to be in line with international standards It is reported that in recent half a year, many pharmaceutical enterprises have been focusing on the opportunity of new drug development and accelerating the process of new drug research and development by going abroad to acquire enterprises "This strategy is right In addition, some young people have learned from overseas and returned home to establish their own R & D and design in China, but it will take time, and it is possible to do so in about ten years " Lu Kongming told reporters that the establishment of a new drug industry must start from cell experiments, animal experiments, human experiments, etc., from research and development to establishment, fast three to five years, slow one to 20 years "But the situation in Taiwan is not the same, because the market in Taiwan is small, the development of the pharmaceutical industry must be the best in the field to be sold, so it has a certain leading position." "So the mainland and Taiwan should take this opportunity to strengthen communication and cooperation in new drugs, and also work together in the special diseases of Chinese on both sides of the Straits, such as cancer and hepatitis." Said Lu Kongming After the meeting, Zhang Wenchang, executive director of the national livelihood medical industry strategy Association, said that the biotechnology industry is universal in the world After today's cross-strait communication and exchanges between the private heavyweight pharmaceutical enterprises, we should strengthen the implementation and further promote cross-strait pharmaceutical industry cooperation Song Ruilin, executive chairman of the China Association for the promotion of drugs, said that the two sessions have strong willingness to promote exchanges and cooperation This year, the two sessions will come up with one or two specific proposals, including a timetable, to promote cross-strait cooperation "The focus in the future is not what to discuss, but what to do." Shao Ying, vice president of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., believes that at present, the initiative of cross-strait pharmaceutical industry is not enough We should combine the capital and market advantages of the mainland with the technological advantages of Taiwan as soon as possible to promote cross-strait pharmaceutical cooperation The day's event was co sponsored by China pharmaceutical innovation promotion association and Taiwan biotechnology and medical industry policy promotion association People from both sides of the pharmaceutical industry also discussed how to accelerate the establishment and integration of cross-strait innovative drug cooperation Some participants called for the current slow progress of cross-strait pharmaceutical cooperation Next, we should strengthen legal convergence and establish a platform for cross-strait drug docking, mutual recognition and access